Literature DB >> 33482896

Effectiveness of a pathway-driven eHealth-based integrated care model (PEICM) for community-based hypertension management in China: study protocol for a randomized controlled trial.

Zheyu Wang1, Chengling Li2, Wencai Huang3, Yan Chen1, Yuqiong Li2, Libin Huang3, Mei Zhang2, Dan Wu1, Li Wang3, Huilong Duan1, Jiye An1, Ning Deng4.   

Abstract

BACKGROUND: The prevalence of hypertension is high and increasing in China in recent years. The treatment and control of hypertension calls for long-term management beyond hospital, which is hard to implement in traditional care settings. Integrated care combined with information technology can promote high-quality healthcare services across the life-course. However, few studies have applied a customized integrated care model in community-based hypertension management in China, catering to the emerging "three-manager" mode. This study aims to identify the effectiveness of a pathway-driven eHealth-based integrated model that implemented as a full-featured telehealth system to facilitate standardized management of hypertension in China.
METHODS: The trial has been designed as a 1-year, non-blinded superiority trial with two parallel groups. A total of 402 hypertensive patients who meet the eligibility criteria will be recruited and randomized with a 1:1 allocation. All the participants will receive a mobile device for self-management, which is a part of our telehealth system. Participants in the control group will only use the device for BP measurement and receive regular follow-ups from care providers according to the guidelines. Participants in the intervention group will gain full access to the system and receive intervention based on the proposed model (a well-designed coordinated care pathway consisting of 9 tasks). Outcomes will be measured mainly on three occasions (at inclusion, at 6 months, and at 12 months). The primary outcome is mean change in systolic blood pressure over a 12-month period. Secondary outcomes include changes in diastolic blood pressure, biochemical indexes related to hypertension, lifestyles, self-management adherence, and hypertension awareness, as well as work efficiency of care providers. DISCUSSION: This study aims to investigate whether a pathway-driven eHealth-based integrated care model based on the "three-manager" mode will improve hypertension control in China. Success of the model would help improve the quality of present community-based management procedures and benefit more patients with uncontrolled hypertension. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1900027645 . Registered on November 22, 2019.

Entities:  

Keywords:  Community; Hypertension management; Integrated care; Pathway; Randomized controlled trial; Study protocol; Telehealth

Mesh:

Year:  2021        PMID: 33482896      PMCID: PMC7820518          DOI: 10.1186/s13063-021-05020-2

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


  34 in total

1.  Improving primary care for patients with chronic illness.

Authors:  Thomas Bodenheimer; Edward H Wagner; Kevin Grumbach
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

2.  [Practice, role and position of nurses in primary care in six European countries, in Ontario and in Quebec].

Authors:  Yann Bourgueil; Anna Marek; Julien Mousques
Journal:  Rech Soins Infirm       Date:  2008-06

3.  2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension.

Authors: 
Journal:  J Geriatr Cardiol       Date:  2019-03       Impact factor: 3.327

4.  Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial.

Authors:  Richard J McManus; Jonathan Mant; Emma P Bray; Roger Holder; Miren I Jones; Sheila Greenfield; Billingsley Kaambwa; Miriam Banting; Stirling Bryan; Paul Little; Bryan Williams; F D Richard Hobbs
Journal:  Lancet       Date:  2010-07-08       Impact factor: 79.321

5.  Using telehealth in the management of hypertension.

Authors:  Charlotte Elizabeth Harrison; Karen Wild
Journal:  Nurs Stand       Date:  2017-07-26

6.  Effects and cost-effectiveness of a guideline-oriented primary healthcare hypertension management program in Beijing, China: results from a 1-year controlled trial.

Authors:  Xin Wang; Weiqin Li; Xian Li; Ning An; Hao Chen; Stephen Jan; Guanghua Ming; Qi Hua; Xiaowei Yan; Ningling Sun; Dong Zhao; Yangfeng Wu
Journal:  Hypertens Res       Date:  2012-11-15       Impact factor: 3.872

7.  Hypertension Knowledge-Level Scale (HK-LS): a study on development, validity and reliability.

Authors:  Sultan Baliz Erkoc; Burhanettin Isikli; Selma Metintas; Cemalettin Kalyoncu
Journal:  Int J Environ Res Public Health       Date:  2012-03-22       Impact factor: 3.390

8.  The eHealth Enhanced Chronic Care Model: a theory derivation approach.

Authors:  Perry M Gee; Deborah A Greenwood; Debora A Paterniti; Deborah Ward; Lisa M Soederberg Miller
Journal:  J Med Internet Res       Date:  2015-04-01       Impact factor: 5.428

9.  A coordinated PCP-Cardiologist Telemedicine Model (PCTM) in China's community hypertension care: study protocol for a randomized controlled trial.

Authors:  Lei Xu; Wei-Yi Fang; Fu Zhu; Hong-Guang Zhang; Kai Liu
Journal:  Trials       Date:  2017-05-25       Impact factor: 2.279

Review 10.  To what extent do primary care practice nurses act as case managers lifestyle counselling regarding weight management? A systematic review.

Authors:  Sonja M E van Dillen; Gerrit J Hiddink
Journal:  BMC Fam Pract       Date:  2014-12-10       Impact factor: 2.497

View more
  1 in total

1.  Exploring and Characterizing Patient Multibehavior Engagement Trails and Patient Behavior Preference Patterns in Pathway-Based mHealth Hypertension Self-Management: Analysis of Use Data.

Authors:  Dan Wu; Xiaoyuan Huyan; Yutong She; Junbin Hu; Huilong Duan; Ning Deng
Journal:  JMIR Mhealth Uhealth       Date:  2022-02-03       Impact factor: 4.773

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.